The present invention relates to transdermal drug delivery system of pharmaceutical compositions, which have a satisfactory in-vitro performance and good bioavailability. In particular, the transdermal pharmaceutical composition of clobazam in the present invention includes a micro-emulsion in liquid or semi solid form, in a dosage form adapted for transdermal delivery (e.g., transdermal patch) for treatment of certain types of epilepsy and anxiety for continues application.

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

The invention provides a composition and pharmaceutical formulation including a peptide immobilized in a hydro gel. Compositions and formulations of the invention are useful in reducing the size, severity or duration of a wound, ameliorating of one or more symptoms associated with a wound without necessarily curing the wound, or lessening in the growth or severity of a wound. Compositions and formulations of the invention are particularly useful in the treatment of a wound associated with diabetes, such as a diabetic ulcer.

The present invention provides a composition for external application comprising baclofen or a salt thereof, specifically baclofen hydrochloride with high transdermal absorbability and stability, and a method of stabilizing a preparation comprising baclofen or a salt thereof.

Provided is a transdermal absorption preparation that shows superior skin permeability of a drug and that does not easily cause cold flow. A transdermal absorption preparation having a drug-containing layer containing a drug and a polymer, wherein 50-100 wt % of the polymer in the drug-containing layer is a polymer having a glass transition temperature of 30° C.-200° C., and the drug in the drug-containing layer is in an amorphous state.

A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl.

A multi-layer transdermal drug delivery system containing ibuprofen or a structural analogue thereof, comprising a transdermal patch containing ibuprofen or a structural analogue thereof and a second combined layer. The transdermal patch comprises a polymer matrix layer, the polymer matrix layer comprising an active ingredient, a compound containing at least one amino group, and a pressure-sensitive adhesive. All or some of active ingredient-amino compound salts or all or some of free active ingredients formed in the polymer matrix layer are kept in a uniform dissolution state in the polymer matrix, and can be stably stored before use, without recrystalization. The transdermal drug delivery system can continuously and controllably deliver a therapeutically effective amount of ibuprofen or a structural analogue thereof for 12 to 24 hours in the absence of a transdermal enhancer, has excellent wearing ability, and avoids a cold flow phenomenon.

A periocular dressing includes a base layer composed of a nonwoven material; a top layer having a composition bound to a polyurethane film, the composition including a hydrogel with a percentage by weight of bacitracin, the top layer to come into contact with a user's skin; and a removable membrane secured over the top layer and to be removed; the polyurethane film of the top layer is adhesively secured to the base layer; and the top layer promotes vasoconstriction and antibacterial properties.

A planar product for treatment of the urogenital tract having a proximal face and a distal face including at least one textile layer (4). The proximal face being coated with an antimicrobially and/or antiseptically effective agent. The planar product has a vitality of >80% after 18 h of incubation time in a Cytotoxicity Test described herein and an efficacy of <80% in a PI-MIA Test described herein.

The inventive transdermal therapeutic systems (TTS) incorporate a timing device, such as an electronic timing device, particularly a thin, electronic timing device. The timing device can be a part of, adhered to, or used in lieu of the TTS backing layer. The device generally includes a pre-programmed or pre-designated timer, an activation and/or reset button to start or reset the timer and an indicator, such as a visual indicator, to alert the patient when the administration time period has lapsed.